PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
Contact information
Jason Sang Hyun Park
Business Development Manager
(+82)02-6959-9489
Jason.Park@proteina.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Award-winning Once Again: ChargePost from ADS-TEC Energy Honored with German Innovation Award 202415.5.2024 17:33:00 EEST | Press release
ADS-TEC Energy today announced that ChargePost has won a German Innovation Award in the category Excellence in Business to business: E-Mobility Technologies, recognizing its design, brand, and innovation. ChargePost is a battery-buffered fast charging station developed and produced in Germany that enables off-grid ultra-fast charging of EVs within minutes. In a statement, the jury said, "With the ChargePost fast charging station from ADS-TEC Energy, long waiting times when charging electric cars are a thing of the past, as the system always maintains a high charging capacity thanks to the buffer battery. In this way, ChargePost offers off-grid charging within a few minutes, which is particularly attractive for fleet vehicles and company parking lots, but also for supermarkets and other businesses with parking spaces. Two large HD screens positioned on the sides attract attention and offer striking opportunities for advertising and information. ChargePost is an attractive solution for t
Jennifer Schneider Elected to Vertex Board of Directors15.5.2024 17:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural America. Prior to founding Homeward in 2022, Dr. Schneider served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions including diabetes, hypertension, obesity and behavioral health issues. While there, she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served as Chief Medical Officer of Castlight Heal
CRN Recognizes Noel Loughrin, Katherine Hou, and Kristen Petruzzelli of Laserfiche on the 2024 Women of the Channel List15.5.2024 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — announced today that CRN ® , a brand of The Channel Company, has named Noel Loughrin, Katherine Hou, and Kristen Petruzzelli to the Women of the Channel list for 2024. These channel leaders are an instrumental part of Laserfiche’s success, which includes growing the Laserfiche channel’s footprint and expertise in various industries. Loughrin, Hou, and Petruzzelli are committed to providing the resources and support that enable solution providers to drive digital transformation at organizations around the world. As senior strategic solutions manager for the public sector, Loughrin is a passionate technologist and Laserfiche advocate. Loughrin works with organizations in local, state, and federal governments, as well as education, to bring about transformative change for constituents, students, and staff. She puts her public sector expertise at the service of Laserfiche channel part
Andersen Global Launches Member Firm in Belgium15.5.2024 16:30:00 EEST | Press release
Andersen Global debuts Andersen in Belgium, as Seeds of Law, a collaborating firm since 2022, becomes the first member firm in the country to adopt the Andersen brand. Andersen in Belgium is a full-service law firm led by partners and co-founders Leo Peeters and Koen de Puydt; and Jan Ghysels, who joined the executive committee in 2022. The firm specializes in corporate and commercial law, real estate, construction, administrative law, and employment law. Additionally, the team works closely with domestic and international clients, including small- and medium-sized enterprises, stock exchange-listed companies, and entrepreneurs. “Working with the member and collaborating firms over the past few years has bolstered our firm’s capabilities and strengthened our firm’s position in the market,” Leo said. “Adopting the Andersen brand reflects our dedication to providing clients with multidisciplinary, seamless solutions to meet their evolving needs inside and outside of Belgium.” Global chai
EM-Power Europe: Flexible Consumers Take the Burden Off the Grid15.5.2024 16:13:00 EEST | Press release
Climate-neutral power generation from solar and wind will place several new challenges on the energy system. Key is that a significantly higher degree of flexibility will be required compared to today to keep supply and consumption in balance. Flexible consumers can make a significant contribution to this. How this can be achieved will be an important topic at EM-Power Europe, the international trade fair for energy management and integrated energy solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515343343/en/ EM-Power Europe 2024 presents a wide range of solutions for more digitalization and flexibility. (Photo: Solar Promotion GmbH) "According to EU calculations, the demand for flexibility will increase by 133 percent between now and 2030," explains Michael Villa, Managing Director of the European industry association smartEn. In a recent study, Agora Energiewende came to the conclusion that by 2035, electric c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom